Condition: Carcinoma, Hepatocellular · Sponsor: Asan Medical Center
This is a phase 2, open-label study to evaluate the safety, tolerability and efficacy of Irpagratinib in combination with Atezolizumab and Bevacizumab in patients with advanced or unresectable HCC harboring FGF19 overexpression. This study composes two parts, a Safety Run-in part to evaluate safety and establish the dose of Irpagratinib for the triple combination, and an Expansion part to evaluate the preliminary efficacy and safety using Simon's two-stage design.
This description comes directly from the study's public registry record.
Changhoon Yoo · 82-2-3010-1727 · cyoo.amc@gmail.com
Always discuss trial participation with your own doctor first.
| Asan Medical Center, | Seoul, South Korea | Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Not Yet Recruiting |
| Severance Hospital | Seoul, South Korea | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07010497